$IQST
iQSTEL Inc Stock $iqst

$iqst Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000166357723000243 Filed on May 15, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$24.67M	$19.42M
YoY Change	27.02%	36.78%
Cost Of Revenue	$23.45M	$18.94M
YoY Change	23.84%	38.11%
Gross Profit	$1.217M	$484.1K
YoY Change	151.36%	-0.68%
Gross Profit Margin	4.93%	2.49%
Selling, General & Admin	$1.440M	$900.1K
YoY Change	59.95%	-39.92%
% of Gross Profit	118.33%	185.95%
Research & Development		$45.16K
YoY Change
% of Gross Profit		9.33%
Depreciation & Amortization	$34.06K	$33.55K
YoY Change	1.52%	63.18%
% of Gross Profit	2.8%	6.93%
Operating Expenses	$1.534M	$978.8K
YoY Change	56.75%	-34.66%
Operating Profit	-$317.5K	-$494.7K
YoY Change	-35.82%	-51.05%
Interest Expense	$192.7K	-$14.89K
YoY Change	-1393.89%	-95.78%
% of Operating Profit
Other Income/Expense, Net	$158.7K	-$4.410K
YoY Change	-3698.82%	-117.95%
Pretax Income	-$158.8K	-$524.7K
YoY Change	-69.73%	-72.07%
Income Tax
% Of Pretax Income
Net Earnings	-$363.2K	-$555.0K
YoY Change	-34.56%	-71.43%
Net Earnings / Revenue	-1.47%	-2.86%
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	-$3.761K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.777M	$4.227M
YoY Change	-57.96%	39.38%
Cash & Equivalents	$1.777M	$4.227M
Short-Term Investments
Other Short-Term Assets	$50.86K	$141.1K
YoY Change	-63.96%	19.77%
Inventory	$26.12K
Prepaid Expenses	$563.2K
Receivables	$3.970M	$2.604M
Other Receivables	$913.3K	$399.6K
Total Short-Term Assets	$6.737M	$7.372M
YoY Change	-8.61%	26.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$433.1K	$398.9K
YoY Change	8.58%	18.81%
Goodwill	$5.172M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$445.1K	$441.3K
YoY Change	0.86%	2.14%
Total Long-Term Assets	$6.150M	$2.478M
YoY Change	148.23%	6.16%
TOTAL ASSETS
Total Short-Term Assets	$6.737M	$7.372M
Total Long-Term Assets	$6.150M	$2.478M
Total Assets	$12.89M	$9.850M
YoY Change	30.84%	20.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.270M	$1.522M
YoY Change	49.2%	-25.99%
Accrued Expenses		$232.7K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$95.41K	$336.1K
YoY Change	-71.61%	-82.56%
Total Short-Term Liabilities	$6.301M	$2.650M
YoY Change	137.81%	-58.66%
LONG-TERM LIABILITIES
Long-Term Debt	$100.3K	$108.4K
YoY Change	-7.55%	-56.37%
Other Long-Term Liabilities	$156.0K	$154.7K
YoY Change	0.86%	2.14%
Total Long-Term Liabilities	$256.2K	$263.1K
YoY Change	-2.61%	-34.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.301M	$2.650M
Total Long-Term Liabilities	$256.2K	$263.1K
Total Liabilities	$6.557M	$1.947M
YoY Change	236.83%	-67.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.87M
YoY Change
Common Stock	$164.6K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.049M	$7.903M
YoY Change
Total Liabilities & Shareholders Equity	$12.89M	$9.850M
YoY Change	30.84%	20.58%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$363.2K	-$555.0K
YoY Change	-34.56%	-71.43%
Depreciation, Depletion And Amortization	$34.06K	$33.55K
YoY Change	1.52%	63.18%
Cash From Operating Activities	$197.2K	-$447.7K
YoY Change	-144.04%	-57.05%
INVESTING ACTIVITIES
Capital Expenditures	$63.25K	-$24.92K
YoY Change	-353.8%	35.8%
Acquisitions
YoY Change
Other Investing Activities	-$79.70K	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$142.9K	-$24.92K
YoY Change	473.62%	-68.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$391.0K	1.368M
YoY Change	-71.42%	-59.96%
NET CHANGE
Cash From Operating Activities	$197.2K	-447.7K
Cash From Investing Activities	-$142.9K	-24.92K
Cash From Financing Activities	$391.0K	1.368M
Net Change In Cash	$447.8K	895.4K
YoY Change	-49.99%	-61.0%
FREE CASH FLOW
Cash From Operating Activities	$197.2K	-$447.7K
Capital Expenditures	$63.25K	-$24.92K
Free Cash Flow	$133.9K	-$422.7K
YoY Change	-131.68%	-58.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001527702
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2022Q1	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1		usd
CY2023Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization		usd
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
CY2022Q1	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties		usd
CY2022Q1	us-gaap	Proceeds From Payments For Long Term Loans For Related Parties ProceedsFromPaymentsForLongTermLoansForRelatedParties		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023Q1	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue		usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q1	IQST	Weighted Average Remaining Life Of Warrants Granted In Period WeightedAverageRemainingLifeOfWarrantsGrantedInPeriod
CY2023Q1	IQST	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Increased By Vwap Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIncreasedByVWAPOutstandingWeightedAverageRemainingLife
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2023Q1	IQST	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Of Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOfForfeited
CY2023Q1	us-gaap	Dividends Dividends		usd
CY2022	us-gaap	Dividends Dividends		usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
CY2022Q1	IQST	Revaluation Of Derivative Liabilities RevaluationOfDerivativeLiabilities		usd
CY2022Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss		usd
CY2022Q4	us-gaap	Financial Guarantee Insurance Contracts Risk Management Activities Mitigating Claim Liabilities Accrued Liabilities FinancialGuaranteeInsuranceContractsRiskManagementActivitiesMitigatingClaimLiabilitiesAccruedLiabilities	79628	usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-55984
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	iQSTEL Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2808620
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	300 Aragon Avenue
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 375
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Coral Gables
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33134
CY2023Q1	dei	City Area Code CityAreaCode	954
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	951-8191
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	164596688	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1777226	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1329389	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3969503	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4209125	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	26124	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	26124	usd
CY2023Q1	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	400893	usd
CY2022Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	326324	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	563221	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	545628	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	6736967	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6436590	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	433119	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	401021	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	99592	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	99592	usd
CY2023Q1	us-gaap	Goodwill Goodwill	5172146	usd
CY2022Q4	us-gaap	Goodwill Goodwill	5172146	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	445100	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	440135	usd
CY2023Q1	us-gaap	Assets Assets	12886924	usd
CY2022Q4	us-gaap	Assets Assets	12549484	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2270211	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2254636	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2748968	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2482352	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	26613	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	26613	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	95407	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	94342	usd
CY2023Q1	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	238610	usd
CY2022Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	235949	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	921222	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1357787	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6301031	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6451679	usd
CY2023Q1	us-gaap	Loans Payable To Bank LoansPayableToBank	100255	usd
CY2022Q4	us-gaap	Loans Payable To Bank LoansPayableToBank	108150	usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	155978	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	154238	usd
CY2023Q1	us-gaap	Liabilities Liabilities	6557264	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6714067	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1200000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	164596688	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161595511	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	164597	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	161595	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31784606	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31136120	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24867580	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24504395	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-32753	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-33557	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7048901	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6759794	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	-719241	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-924377	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6329660	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5835417	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12886924	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12549484	usd
CY2023Q1	us-gaap	Revenues Revenues	24666529	usd
CY2022Q1	us-gaap	Revenues Revenues	19419311	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	23449793	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	18935251	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	1216736	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	484060	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1534266	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	989498	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1534266	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	989498	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-317530	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-505438	usd
CY2022Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	24159	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-33954	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-28564	usd
CY2023Q1	IQST	Interest Expense2 InterestExpense2	3645	usd
CY2022Q1	IQST	Interest Expense2 InterestExpense2	14888	usd
CY2023Q1	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1	196307	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	158708	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19293	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-158822	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-524731	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-158822	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-524731	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	204363	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	30239	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-363185	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-554970	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-158822	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-524731	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	-1577	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	384	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-157245	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-525115	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	205136	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	30051	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-362381	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-555166	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q1	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	164034479	shares
CY2022Q1	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	147539580	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6759794	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	400000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11230	usd
CY2023Q1	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	240258	usd
CY2023Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	804	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-363185	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7048901	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7416911	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1000000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	41139	usd
CY2022Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-196	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-554970	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	7902884	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-158822	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-524731	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11230	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	41139	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	34060	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	33547	usd
CY2022Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	7407	usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-196307	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-564365	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	87361	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16204	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-24677	usd
CY2023Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-5131	usd
CY2022Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-23316	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	537667	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	73445	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-583957	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-39091	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	197163	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-447652	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	63247	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24918	usd
CY2023Q1	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	80000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Long Term Loans For Related Parties ProceedsFromPaymentsForLongTermLoansForRelatedParties	300	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-142947	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24918	usd
CY2023Q1	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	9006	usd
CY2022Q1	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	232018	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1100000	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	400000	usd
CY2022Q1	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	500000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	390994	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1367982	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2627	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3181	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	447837	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	892231	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1329389	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3334813	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1777226	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4227044	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	3333	usd
CY2023Q1	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	240258	usd
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2011-06-24
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zSzY3BW6GWYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	20000	usd
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	129967	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	120139	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	20450	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	26600	usd
CY2023Q1	us-gaap	Advance Payments Netted Against Claim Receivable AdvancePaymentsNettedAgainstClaimReceivable	21000	usd
CY2022Q4	us-gaap	Advance Payments Netted Against Claim Receivable AdvancePaymentsNettedAgainstClaimReceivable	21000	usd
CY2023Q1	us-gaap	Income Tax Receivable IncomeTaxReceivable	394	usd
CY2022Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	389	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	362000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	357500	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	20000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	9410	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	563221	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	545628	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1125142	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1057650	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	-692023	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	-656629	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	433119	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	401021	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34060	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	33547	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	195662	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	202492	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	195662	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	202492	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	95407	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	94342	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	100255	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	108150	usd
CY2023Q1	us-gaap	Loans Payable LoansPayable	238610	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	235949	usd
CY2023Q1	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	238610	usd
CY2022Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	235949	usd
CY2023Q1	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_80B_eus-gaap--DerivativesReportingOfDerivativeActivity_zh7htohCwzZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 – WARRANTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On April 5, 2022, we entered into a Common Stock Purchase Option Agreement with Apollo Management Group, Inc (Holder) to subscribe for and purchase from the Company, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220405__20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zo6pfi14q8Ke">4,800,000</span> shares of Common Stock with an exercise price per share of $2.00; and an initial exercisable date on <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20220405__20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zbBGHpKqlg72">September 30, 2022</span>. The purchase price of this option was <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_z7anichmzoej">$500,000</span>. The Company determined that the warrants had a fixed monetary value with a variable number of shares at inception and categorized the warrants as a liability in the accompanying consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_900_eus-gaap--OptionIndexedToIssuersEquitySettlementAlternatives_c20220405__20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zm1FjQPPlI99">The Holder and the Company agreed that the Holder had the right and the obligation to exercise, on a cashless basis, $1,000,000 of the Options not later than October 15, 2022</span>. Thereafter, the Holder shall undertake to exercise not less than (i) <span id="xdx_900_eus-gaap--OptionIndexedToIssuersEquitySettlementAlternativesCashAtFairValue_iI_c20221114__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zl32QM4Ek2pg"><span id="xdx_90B_eus-gaap--WarrantsNotSettleableInCashFairValueDisclosure_iI_c20221114_zTjhg8QOICsh">$400,000</span></span> of the Options on a “cash basis” not later than the later of (y) <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20221114__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zUX8juKsaWwf">November 14, 2022</span> or (z) the date on which there is an effective registration statement permitting the issuance of the Option Shares to or resale of the Option Shares by the Holder and (ii) an additional <span id="xdx_905_eus-gaap--OptionIndexedToIssuersEquitySettlementAlternativesCashAtFairValue_iI_c20221214__us-gaap--DebtInstrumentAxis__custom--ApolloOptionAdditionalMember_zpcEyw5Hx5B3">$400,000</span> of the Options on a “cash basis” not later than the latest of (x) thirty (30) days following the exercise of the Option under subsection (i), above, (y) December 14, 2022, or (z) the date on which there is an effective registration statement permitting the issuance of the Option Shares to or resale of the Option Shares by the Holder. From and after the occurrence of the three above-referenced exercises, each additional exercise of Options hereunder shall be in an amount not less than <span id="xdx_90D_eus-gaap--OptionIndexedToIssuersEquitySettlementAlternativesCashAtFairValue_iI_c20221214__us-gaap--DebtInstrumentAxis__custom--ApolloOptionEachAdditionalMember_zES9qKeWoK97">$200,000 </span>and exercised only on a cash basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90A_eus-gaap--DebtInstrumentCallFeature_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ApolloManagementGroupMember_zAcYCz34Rjhg">The Holder’s obligation to exercise each specified portion of this option on the specific dates above is subject to the volume-weighted average price (“VWAP”, market value), being not less than $0.20 per share on the relevant option exercise date. Adjusted option shares at VWAP of $0.20 shall be 48,000,000 shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of activity regarding warrants issued as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zHXYubaUvi6h" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto" summary="xdx: Disclosure - NOTE 7 - WARRANTS - Schedule of Warrant Summary (Details)"> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Warrants Outstanding</b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="3"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td><b> </b></td> <td colspan="3"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Weighted Average</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Weighted Average Remaining</b></td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Warrants</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Exercise Price</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Contractual life (in years)</b></td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 47%; padding-left: 5.4pt">Outstanding, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20221231_z78TTjkoaQA3">23,112,575</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20221231_z9hpHPWM286i">0.17</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231_zYZ15ypSdUt">0.75</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230331_zim5C4DJpkr7"><span style="-sec-ix-hidden: xdx2ixbrl0656">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331_zLX7eNBsR2Q9"><span style="-sec-ix-hidden: xdx2ixbrl0657">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_ecustom--WeightedAverageRemainingLifeOfWarrantsGrantedInPeriod_d0_c20230101__20230331_z1ydReCOtkAg"><span style="-sec-ix-hidden: xdx2ixbrl0658">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Increase in number of warrants by VWAP</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20230101__20230331_zN5eSrtxDK98">5,262,465</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_ecustom--IncreaseInNumberOfWarrantsWeightedAverageExercisePrice_c20230101__20230331_z0ihB3NUU5Cf">0.14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIncreasedByVWAPOutstandingWeightedAverageRemainingLife_d0_c20230101__20230331_z7v8QxC58aY2"><span style="-sec-ix-hidden: xdx2ixbrl0661">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230331_zDf3Vxpf0Gjk">2,941,177</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331_zrer9Rkhc0ee">0.14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331_z5yUXNOQWg9b">0.70</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5.4pt">Forfeited/canceled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20230331_zuCtquxU5fXg"><span style="-sec-ix-hidden: xdx2ixbrl0665">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20230331_zbcN4Nu3cR1i"><span style="-sec-ix-hidden: xdx2ixbrl0666">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOfForfeited_d0_c20230101__20230331_zsRXPtAZUkI9"><span style="-sec-ix-hidden: xdx2ixbrl0667">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">Outstanding, March 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20230331_zgz2Ql78eJLg">25,433,863</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20230331_zcULqLXRPLs1">0.14</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230331_zby3q6iBrMh6">0.50</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>
CY2022Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	400000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	23112575	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.17
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y9M
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease	5262465	shares
CY2023Q1	IQST	Increase In Number Of Warrants Weighted Average Exercise Price IncreaseInNumberOfWarrantsWeightedAverageExercisePrice	0.14
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	2941177	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.14
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P0Y8M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	25433863	shares
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.14
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y6M
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0467	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0494	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0006	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0473	pure
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	1357787	usd
CY2023Q1	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	240258	usd
CY2023Q1	us-gaap	Debt Securities Held To Maturity Transfer Derivative Hedge Gain Loss DebtSecuritiesHeldToMaturityTransferDerivativeHedgeGainLoss	196307	usd
CY2023Q1	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	921222	usd
CY2023Q1	IQST	Revaluation Of Derivative Liabilities RevaluationOfDerivativeLiabilities	196307	usd
CY2023Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	196307	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	60000	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11230	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	400000	usd
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	164596688	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161595511	shares
CY2023Q1	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	400893	usd
CY2022Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	326324	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	26613	usd
CY2022Q1	us-gaap	Management Fee Expense ManagementFeeExpense	144000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	11230	usd
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	41139	usd
CY2023Q1	us-gaap	Financial Guarantee Insurance Contracts Risk Management Activities Mitigating Claim Liabilities Accrued Liabilities FinancialGuaranteeInsuranceContractsRiskManagementActivitiesMitigatingClaimLiabilitiesAccruedLiabilities	104628	usd
CY2023Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	900	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	20150	usd
CY2023Q1	us-gaap	Revenues Revenues	24666529	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	23449793	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	1216736	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1534266	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-317530	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	158708	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-158822	usd
CY2022Q1	us-gaap	Revenues Revenues	19419311	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	18935251	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	484060	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	989498	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-505438	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19293	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-524731	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	6736967	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	6149957	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6301031	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	256233	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6436590	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6112894	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6451679	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	262388	usd

Files In Submission

Name	View Source	Status
0001663577-23-000243-index-headers.html	Edgar Link	pending
0001663577-23-000243-index.html	Edgar Link	pending
0001663577-23-000243.txt	Edgar Link	pending
0001663577-23-000243-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
iqst-20230331_cal.xml	Edgar Link	unprocessable
iqst-20230331_lab.xml	Edgar Link	unprocessable
image_001.jpg	Edgar Link	pending
iqst-20230331.xsd	Edgar Link	pending
iqst10q_033123.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
iqst10q_033123_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending
iqst-20230331_def.xml	Edgar Link	unprocessable
iqst-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IQST
iQSTEL Inc Stock $iqst

2023 Q1 Form 10-Q Financial Statement

#000166357723000243 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IQST iQSTEL Inc Stock $iqst

2023 Q1 Form 10-Q Financial Statement

#000166357723000243 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IQST
iQSTEL Inc Stock $iqst